Predictive markers of ibd
AssigneeNestec S.A.
InventorsEduardo Schiffrin, Viral Brahmbhatt, Francois-Pierre Martin, Ivan Montoliu Roura, Serge Andre Dominique Rezzi, Jalil Benyacoub
Life of this patent
Estimating the term…
Abstract
The invention relates to a method, a system and kit for identifying the sample of a patient having IBD or predicting the relapse of IBD in patients based on the measurement of biomarkers in a sample of the patient. The biomarkers can be lipids or amino acids or a combination thereof.
Claims21
An ex vivo analytical method of determining whether a subject has inflammatory bowel disease (IBD), comprising:
- providing an isolated biological sample;
- measuring the concentration of at least two biomarkers in the sample;
- wherein the concentration is significantly lower or higher than a reference value for the biomarkers indicates that the subject has inflammatory bowel disease,
- wherein a first biomarker is a lipid selected from the group consisting of glycerophospholipid, sphingolipid and combinations thereof and at least one further biomarker is an amino acid selected from a group consisting of arginine, glutamine, glycine, histidine, isoleucine, leucine, ornithine, serine, threonine, tryptophane, tyrosine phenylalanine, and valine and combinations thereof.
A system for determining whether a subject has inflammatory bowel disease, the system comprising a device for measuring the concentration of the biomarkers through a method comprising:
- providing an isolated biological sample;
- measuring the concentration of at least two biomarkers in the sample;
- wherein the concentration is significantly lower or higher than a reference value for the biomarkers indicates that the subject has inflammatory bowel disease, wherein a first biomarker is a lipid selected from the group consisting of glycerophospholipid, sphingolipid and combinations thereof and at least one further biomarker is an amino acid selected from a group consisting of arginine, glutamine, glycine, histidine, isoleucine, leucine, ornithine, serine, threonine, tryptophane, tyrosine phenylalanine, and valine and combinations thereof, the system comprising a computer:
- the computer stores a data base comprising reference values for the concentrations of the biomarkers;
- the computer stores a software program having instructions causing the computer
- to receive and store the measured values of the parameters of the sample of a subject;
- to compare values of said measured parameters to the reference values stored in the system;
- indicate the sample as belonging to a subject having inflammatory bowel disease if the measured values differ from the reference values;
- and
- output the results of step iii.
A kit for determining whether a subject has inflammatory bowel disease comprising reagents for measuring the concentration of the biomarkers through a method comprising:
- providing an isolated biological sample;
- measuring the concentration of at least two biomarkers in the sample;
- wherein the concentration is significantly lower or higher than a reference value for the biomarkers indicates that the subject has inflammatory bowel disease, wherein a first biomarker is a lipid selected from the group consisting of glycerophospholipid, sphingolipid and combinations thereof and at least one further biomarker is an amino acid selected from a group consisting of arginine, glutamine, glycine, histidine, isoleucine, leucine, ornithine, serine, threonine, tryptophane, tyrosine phenylalanine, and valine and combinations thereof.
Dependencies are inferred from the claim text.